Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.

17 Dec 2009

Adimab announces initiation of research collaborations with two other companies

Adimab, Inc., a leader in the discovery of fully human antibodies, today announced the initiation of research collaborations with Pfizer and an undisclosed second company. Adimab also announced the receipt of milestone payments from two recently announced discovery collaborations with Merck and Roche.

17 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint was achieved in the Company’s Phase 2 pain study assessing the efficacy and safety of BEMA Buprenorphine. The positive results follow BDSI’s March 2009 announcement of favorable Phase 1 study results.

17 Dec 2009

New Tandem fund of $300 million presents financing option for Canada’s biotechnology industry

The new Tandem fund of $300 million announced last week presents a much-needed financing option for Canada’s biotechnology industry. The Fund received investments from the Business Development Bank of Canada (BDC), and Export Development Canada (EDC), contributing $80 and $75 million respectively to the Fund.

17 Dec 2009

Dangers of excess radiation exposure: Stricter measures needed to prevent unnecessary scans

MedSolutions (www.medsolutions.com), a leading provider of medical cost management services, today commended two new studies highlighting the dangers of excess radiation exposure from CT scans and other diagnostic imaging tests.

17 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

Silence Therapeutics and Intradigm merge to form RNAi

The Boards of Silence Therapeutics plc and Intradigm Corporation are delighted to announce the merger of their businesses to form a leading company in the field of RNAi (RNA interference).

17 Dec 2009

ODAC to review Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).

17 Dec 2009

ODAC to conduct public advisory meeting to review ChemGenex Pharmaceuticals’ NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today the U.S. Food and Drug Administration (FDA) has notified the company that the Oncologic Drugs Advisory Committee (ODAC) will conduct a public advisory meeting on 10 February 2010 to review the Company’s NDA for Omapro™ (omacetaxine mepesuccinate) for injection.

17 Dec 2009

JCTM established to advance new research toward clinical applications

The California Institute of Technology (Caltech) and the University of California, Los Angeles (UCLA) have announced the establishment of the Joint Center for Translational Medicine (JCTM), which will advance experimental research into clinical applications, including the diagnosis and therapy of diseases such as cancer.

17 Dec 2009

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Aided by next-generation DNA sequencing technology, an international team of researchers has gained insights into how more than 60 carcinogens associated with cigarette smoke bind to and chemically modify human DNA, ultimately leading to cancer-causing genetic mutations.

17 Dec 2009

$15 million federal funds for new cancer research program

As a result of C3: Colorectal Cancer Coalition's advocacy efforts, $15 million for a new peer reviewed cancer research program is included in the final Fiscal Year 2010 Defense Appropriations Bill.

17 Dec 2009

Human MicroRNA Panel for gene-expression profiling to be launched by WaferGen Biosystems

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced that it will be launching the Human MicroRNA Panel for its innovative service for gene-expression profiling using its SmartChip(TM) Real-Time PCR System.

17 Dec 2009

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced that Cancer Research UK’s Drug Development Office – the drug development arm of the world’s largest independent organization dedicated to cancer research – is standardizing on Phase Forward’s InForm™ Global Trial Management solution to support its diverse portfolio of early-stage clinical trials.

17 Dec 2009

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc., of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

New research building at Children's Hospital of Philadelphia receives LEED certification

Building materials that better retain heat in the winter, and reflect it in the summer; plumbing fixtures that save water; and facilities that encourage employees to bicycle to work. Environmentally-friendly features like these enable the new research building at The Children's Hospital of Philadelphia to be certified as a green structure.

16 Dec 2009

Spiritual care can improve outcomes in terminally ill cancer patients

In a new study of terminally ill cancer patients, researchers at Dana-Farber Cancer Institute found support of patients' spiritual needs by the medical team is associated with greater use of hospice, less aggressive care, and greater quality of life near death. The

16 Dec 2009

Oncology News and Research

Further Reading

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Adimab announces initiation of research collaborations with two other companies

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

New Tandem fund of $300 million presents financing option for Canada’s biotechnology industry

Dangers of excess radiation exposure: Stricter measures needed to prevent unnecessary scans

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Silence Therapeutics and Intradigm merge to form RNAi

ODAC to review Cell Therapeutics' NDA for pixantrone

ODAC to conduct public advisory meeting to review ChemGenex Pharmaceuticals’ NDA for Omapro

JCTM established to advance new research toward clinical applications

Researchers discover new gene involved in lung cancer using DNA sequencing technology

$15 million federal funds for new cancer research program

Human MicroRNA Panel for gene-expression profiling to be launched by WaferGen Biosystems

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

New research building at Children's Hospital of Philadelphia receives LEED certification

Spiritual care can improve outcomes in terminally ill cancer patients

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News